Completed Research: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CR14

Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies

JHOP - March 2023 Vol 13 Special Feature - HOPA Abstracts

Presenters: Caroline M. Mejías-De Jesús, PharmD, BCOP, Beth Israel Deaconess Medical Center, Boston, MA; Lauren McGinty, PharmD, BCOP, Beth Israel Deaconess Medical Center, Boston, MA

Co-Authors: Verona Abdelmeseh, PharmD, BCOP, Northshore University Hospital, Manhasset, NY; Ajoy Dias, MD, MRCP, Beth Israel Deaconess Medical Center, Boston, MA

BACKGROUND: The use of venetoclax has benefited numerous patients and has changed the treatment landscape across several hematologic malignancies. However, it brings several challenges, including prolonged hospitalizations for slow dose ramp-ups with frequent monitoring. There are limited data on the safety of escalating doses more rapidly than is described in initial trials and in the prescribing information, but doing so has the potential to benefit patients and the healthcare system by decreasing the number of admissions and lengths of stay associated with treatment initiation.

OBJECTIVE: To evaluate the safety and feasibility of rapid dose escalation of venetoclax in patients with hematologic malignancies.

METHOD: A retrospective chart review was conducted for adults in the inpatient setting with hematologic malignancies who received rapid ramp-ups of venetoclax that deviated from the prescribing information recommendations between January 2018 and June 2022 at Beth Israel Deaconess Medical Center. The safety end points included the proportion of patients who had tumor lysis syndrome (TLS) per the Cairo-Bishop criteria and other adverse events (AEs) during the ramp-up. Feasibility was measured by the proportion of patients achieving the target 400-mg dose or an alternative stable dose. Descriptive statistics were calculated.

RESULTS: A total of 22 patients received a rapid dose escalation of venetoclax. The median age at venetoclax initiation was 68.5 years (range, 51-87 years). The most common indications included mantle-cell lymphoma (N = 6; 27.3%), relapsed/refractory chronic lymphocytic leukemia (CLL; N = 5; 22.7%), and de novo CLL (N = 4; 18.2%). A total of 10 (52.6%) patients received B-cell receptor pathway inhibitor therapy immediately before receiving venetoclax. All patients started the ramp-up in the inpatient setting with TLS monitoring. The most common schedule (9.1%) was 20 mg on day 1 of week 1, 50 mg on days 2 and 3 of week 1, 100 mg on days 4 through 7 of week 1, 200 mg on days 1 through 7 of week 2, and then 400 mg daily. All but 1 patient received appropriate TLS prophylaxis. In all, 19 (86.4%) patients completed the ramp-up and achieved the 400-mg target dose. A total of 3 (13.6%) patients achieved a stable dose of 200 mg as a result of drug–drug interactions or AEs. The median time to a target or stable dose was 14 days (range, 4-39 days). Laboratory TLS occurred in 1 (4.5%) patient at the 20-mg dose, which resolved without intervention; 2 (9.1%) patients at the 50-mg dose, 1 of which resolved without intervention and the other required treatment with rasburicase and sevelamer; and 1 (4.5%) patient at the 200-mg dose, which resolved without intervention. No clinical TLS was reported. Other AEs included anemia (45.5%), thrombocytopenia (36.4%), and neutropenia (31.8%). No discontinuation of venetoclax occurred during the ramp-up.

CONCLUSION: Rapid dose escalation of venetoclax initiated with close inpatient monitoring was tolerated with minimal TLS.

  1. Davids MS, Shadman M, Parikh SA, et al. A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia. Abstract presented at the American Society of Hematology Annual Meeting 2020; Abstract 3145. https://ash.confex.com/ash/2020/webprogram/Paper139885.html.
  2. Koenig KL, Huang Y, Dotson EK, et al. Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. Blood Adv. 2020;4:4860-4863.
  3. Davids M, Jones J, Eradat H, et al. Modified venetoclax dose ramp-up in select high-risk patients with chronic lymphocytic leukemia (CLL) with progression after B-cell receptor pathway inhibitors (BCRi). Clin Lymphoma Myeloma Leuk. 2017;17(suppl 2):302. Abstract CLL-101.
Related Items
Assessing Student Pharmacists’ Knowledge and Perceptions of Financial Toxicity Concepts Introduced in an Oncology Pharmacotherapy Course
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Biodistribution and Shedding Analysis Following RP1 Oncolytic Immunotherapy Dosing in Patients From the IGNYTE Clinical Trial: Implications for Oncology Pharmacists
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Characterizing Second-Line and Beyond Treatments for Primary Central Nervous System Lymphomas
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Coordinating Better Outcomes in Multiple Myeloma: An Educational Initiative to Elevate Pharmacist Leadership in Novel Antibodies and CAR-T Therapy
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Dosing, Safety, and Pharmacokinetics of Combination Therapy With Darolutamide, Androgen-Deprivation Therapy, and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the ARASENS Study
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Evaluating Patient Hesitancy in Receiving a Second Dose of Evusheld (Tixagevimab and Cilgavimab) for COVID-19 Prevention After a Food and Drug Administration Dosing Recommendation Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
First-Line Nivolumab + Ipilimumab + Chemotherapy Versus Chemotherapy Alone in Metastatic Non–Small Cell Lung Cancer: CheckMate 9LA 4-Year Clinical Update
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
Improving Post-Transplant Vaccination Compliance via Implementation of a Clinical Pharmacist–Managed Service
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in HOPA Abstracts
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: